Kanghong Pharmaceutical: Its subsidiary KHN923 injection has been approved for clinical trials
2026-11-18 19:35:29
According to CoinMeta, Kanghong Pharmaceutical announced that its subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., has received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the KHN923 injection. This drug is a Class 1 therapeutic biologic product, indicated for Alzheimer's disease, and is a bispecific antibody targeting the β-amyloid/transferin receptor 1.
Bullish 0
Bearish 0
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.